Skip to content

De-intensification of adjuvant radiotherapy to breast/chest wall in early breast cancer (EBC) patients achieving a pathological complete response (pCR)  to neoadjuvant chemotherapy (NACT) 

We would appreciate your expert opinions and completion of the below survey regarding the feasibility of a trial evaluating omission of adjuvant therapy to the breast/chest wall (CW) following pathological complete response (pCR) (excluding residual DCIS or ITC ie ypT0ypN0) to neoadjuvant chemotherapy in EBC. 
1.Specialty?(Required.)
2.Grade(Required.)
3.Region?(Required.)
4.There is a need for a prospective RCT evaluating de-intensification of adjuvant radiotherapy to the breast/CW in EBC patients who have achieved pCR (excluding DCIS and ITC/micromets)?(Required.)
5.Would you consider entering an EBC patient in to a trial where the omission of breast/CW radiotherapy in a patient with pCR post NACT Ie. (ypT0ypN0), is one of the arms in the trial?(Required.)
6.What would your trial inclusion criteria be?
7.Would you consider entering a patient into a trial of omission of breast/CW and axillary radiotherapy, for a clinically node negative axilla pre-NACT, who has pCR in breast and axilla (ypT0ypN0) but evidence of NACT-related changes in 1-3 nodes?(Required.)
8.What would your exclusion criteria be?
9.Comments